Pharmacoeconomic analysis of the use of gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia in the Russian Federation
In this study, a pharmacoeconomic analysis of chronic lymphocytic leukemia therapy in previously untreated patients was conducted, using treatment regimens obinutuzumab (Gazyva) + chlorambucil and rituximab +chlorambucil. The results of the study showed that though the costs of the first treatment course with obinutuzumab + chlorambucil are significantly higher, this regimen reduces the cumulative cost of subsequent therapy lines in patients with CLL (due to a longer progression-free survival). In the end of the third year of therapy, cumulative costs become relatively similar: with the use of the obinutuzumab + chlorambucil regimen, the cumulative cost per 1 patient/year will be 38,390 rubles higher compared to the rituximab + chlorambucil regimen. At the same time, the obinutuzumab regimen showed a lower cost-effectiveness ratio, i.e. it had an advantage over the alternative technology.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link: Kulikov A.Y., Babiy V. V. Pharmacoeconomic analysis of the use of gazyva (obinutuzumab) for the treatment of chronic lymphocytic leukemia in the Russian Federation // Pharmacoeconomics: theory and practice. - 2015. - Vol.3, №2. - P.61-65 DOI: https://doi.org/10.30809/phe.2.2015.5